Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.


The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2006 1
2007 2
2008 16
2009 20
2010 26
2011 28
2012 23
2013 25
2014 21
2015 28
2016 31
2017 27
2018 14
2019 15
2020 5
2021 3
2022 3
Text availability
Article attribute
Article type
Publication date

Search Results

249 results
Results by year
Filters applied: . Clear all
Page 1
Complement activation promoted by the lectin pathway mediates C3aR-dependent sarcoma progression and immunosuppression.
Magrini E, Di Marco S, Mapelli SN, Perucchini C, Pasqualini F, Donato A, Guevara Lopez ML, Carriero R, Ponzetta A, Colombo P, Cananzi F, Supino D, Reis ES, Peano C, Inforzato A, Jaillon S, Doni A, Lambris JD, Mantovani A, Garlanda C. Magrini E, et al. Nat Cancer. 2021 Feb;2(2):218-232. doi: 10.1038/s43018-021-00173-0. Epub 2021 Feb 18. Nat Cancer. 2021. PMID: 34505065 Free PMC article.
Thirty-Eight-Negative Kinase 1 Is a Mediator of Acute Kidney Injury in Experimental and Clinical Traumatic Hemorrhagic Shock.
Halbgebauer R, Karasu E, Braun CK, Palmer A, Braumüller S, Schultze A, Schäfer F, Bückle S, Eigner A, Wachter U, Radermacher P, Resuello RRG, Tuplano JV, Nilsson Ekdahl K, Nilsson B, Armacki M, Kleger A, Seufferlein T, Kalbitz M, Gebhard F, Lambris JD, van Griensven M, Huber-Lang M. Halbgebauer R, et al. Front Immunol. 2020 Aug 26;11:2081. doi: 10.3389/fimmu.2020.02081. eCollection 2020. Front Immunol. 2020. PMID: 32983160 Free PMC article. Clinical Trial.
Complement C3 vs C5 inhibition in severe COVID-19: Early clinical findings reveal differential biological efficacy.
Mastellos DC, Pires da Silva BGP, Fonseca BAL, Fonseca NP, Auxiliadora-Martins M, Mastaglio S, Ruggeri A, Sironi M, Radermacher P, Chrysanthopoulou A, Skendros P, Ritis K, Manfra I, Iacobelli S, Huber-Lang M, Nilsson B, Yancopoulou D, Connolly ES, Garlanda C, Ciceri F, Risitano AM, Calado RT, Lambris JD. Mastellos DC, et al. Clin Immunol. 2020 Nov;220:108598. doi: 10.1016/j.clim.2020.108598. Epub 2020 Sep 19. Clin Immunol. 2020. PMID: 32961333 Free PMC article.
The first case of COVID-19 treated with the complement C3 inhibitor AMY-101.
Mastaglio S, Ruggeri A, Risitano AM, Angelillo P, Yancopoulou D, Mastellos DC, Huber-Lang M, Piemontese S, Assanelli A, Garlanda C, Lambris JD, Ciceri F. Mastaglio S, et al. Clin Immunol. 2020 Jun;215:108450. doi: 10.1016/j.clim.2020.108450. Epub 2020 Apr 29. Clin Immunol. 2020. PMID: 32360516 Free PMC article.
249 results